Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
ncarol.com/10338216

NEW CITY, N.Y. - ncarol.com -- Baird Medical Investment Holdings Ltd. (N A S D A Q: BDMD) $BDMD is entering an increasingly interesting stage of its corporate evolution. What was once primarily a China-focused microwave ablation company is now pursuing a much broader strategy: expand internationally, establish a meaningful U.S. commercial presence, diversify its technology portfolio and turn its minimally invasive ablation expertise into a global medical technology platform.

The company's latest financial announcement may be the clearest indication yet that this strategy is beginning to produce measurable results.

On September 3, Baird Medical reported approximately $9.9 million in revenue for the first six months of 2026, representing a 24.6% increase over the approximately $8.0 million generated during the comparable period of 2025. Even more noteworthy, approximately two-thirds of first-half revenue came from outside mainland China, with Hong Kong and the United States representing the principal contributing regions.

For investors watching BDMD's international transition, that geographic shift could be one of the most important developments of the year.

The Numbers Are Moving in the Right Direction

Baird's first-half results contained several encouraging operating signals:

• Revenue increased 24.6% to approximately $9.9 million
• Gross profit increased 32% to approximately $8.6 million
• Gross margin improved to 87.0% from 82.1%
• Operating expenses fell dramatically to $7.8 million from $17.0 million
• Net income improved to approximately $14,000 from an $11.4 million loss
• Adjusted EBITDA improved to approximately $4.0 million from negative $3.3 million
• Approximately 27% of first-half revenue came from the United States, compared with less than 2% in the first half of 2025.

The transformation in U.S. contribution is particularly interesting.

Baird isn't simply talking about entering the American market anymore. The company says its U.S. commercial expansion is progressing ahead of plan, with an expanded sales team providing coverage across multiple key territories. Management is also working toward additional product submissions and regulatory clearances.

That creates an intriguing potential growth equation: if U.S. adoption continues to build while the company simultaneously expands internationally, BDMD could become increasingly diversified geographically.

From China Headwinds to a Global Strategy

The importance of this transition becomes clearer when looking at 2025.

Baird reported full-year 2025 revenue of approximately $22.5 million, down from $37.0 million in 2024, with the company attributing much of the decline to policy-driven pricing pressure and reduced procurement activity in mainland China. Rather than remain dependent upon that market, Baird accelerated its geographic diversification strategy.

More on ncarol.com

• TekTone innovation meets patient care
• HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
• Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
• OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
• P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport

That strategy now appears to be gaining traction.

In June, Baird established its global headquarters in New York City, reinforcing its focus on U.S. commercial expansion. The company also appointed experienced med-tech executive Mark Saxton to lead Baird Medical's U.S. operations and commercial ramp.

The significance goes beyond a change of address. New York provides Baird with a more prominent base for its U.S. operations, while the expanding sales organization and physician relationships are designed to support broader adoption of its minimally invasive technology.

International Expansion Continues to Stack Up

Baird's global expansion is also becoming increasingly visible.

In June, physicians in Vietnam and Argentina completed their first microwave ablation procedures using Baird Medical's technology, providing evidence of progression from regulatory and market-entry activity toward actual clinical utilization.

Then, on August 20, Baird announced that Pakistan's Drug Regulatory Authority of Pakistan (DRAP) had granted product registrations for its BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle.

Those registrations build upon Baird's existing Pakistani presence, including earlier regulatory approvals and commercial availability at the Armed Forces Institute of Radiology & Imaging.

For an emerging medical technology company, each new market can potentially expand the addressable customer base while also building clinical experience, physician familiarity and distribution infrastructure.

A Potentially Bigger Story: IRE Technology

Perhaps the most intriguing recent strategic development came August 10.

Baird announced a strategic cooperation agreement with Alpmed, a developer of irreversible electroporation, or IRE, technology.

IRE is a non-thermal ablation technology that uses electrical pulses to destroy targeted tissue while seeking to preserve surrounding structures such as blood vessels and nerves. The companies intend to combine Alpmed's IRE expertise with Baird's regulatory and global commercialization capabilities.

The planned first co-developed product is intended for soft-tissue solid tumors involving the liver, breast, thyroid and prostate.

More importantly for investors, Baird and Alpmed plan to submit a 510(k) application to the FDA by the end of 2026, with potential FDA clearance in 2027.

Baird is expected to lead global regulatory approval efforts and holds worldwide commercialization rights for the IRE product.

That could potentially broaden BDMD's opportunity substantially beyond its established microwave ablation business.

And AI Could Add Another Layer

Baird is simultaneously developing an AI-driven surgical software platform designed to automate clinical workflows including anatomical mapping, treatment planning and procedural simulations.

The company announced in March that it had completed development of its cross-platform surgical software and had begun registration efforts in the United States, European Union and China. The software is also designed to integrate with Baird's planned fully automated surgical robotic system.

More on ncarol.com

• DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
• Crawler Record for WordPress Version 1.0
• French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
• Piedmont Crossing Celebrates 40 Years of Caring, Community, and Connection
• LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood

Taken together, the company's development pipeline points toward something potentially larger than a single-product medical device company:

MWA + IRE + AI software + robotic ablation + international commercialization.

That combination is what makes BDMD particularly interesting to watch.

What Could Investors Be Watching Next?

Several potential catalysts now stand out:

• Continued growth in U.S. MWA utilization and physician adoption
• Additional international regulatory approvals and commercial launches
• Progress toward the planned IRE 510(k) submission
• Additional product regulatory submissions
• Expansion of Baird's U.S. sales organization
• Further evidence that positive earnings and EBITDA can be sustained
• Development and regulatory progress for the company's AI-powered and robotic technologies

There are, of course, meaningful risks. Baird's first-half financial figures are preliminary and unaudited, and the company remains exposed to regulatory, competitive, financing, geopolitical and execution risks. Its history also demonstrates how quickly policy and pricing conditions can affect medical-device businesses.

But the current story is undeniably becoming more interesting.

The Bottom Line

Baird Medical appears to be moving through a significant transition — from a company heavily exposed to the Chinese market toward a more diversified, international minimally invasive medical technology business.

The latest numbers provide tangible evidence of that shift: revenue is growing, margins have improved, operating expenses have fallen sharply, the company has returned to approximately breakeven net income, and U.S. revenue has gone from a negligible portion of the business to approximately 27% of first-half revenue.

At the same time, Pakistan, Vietnam and Argentina are adding to the company's international footprint, while the planned IRE program and AI/robotics initiatives introduce potentially much larger opportunities beyond its current MWA platform.

For investors willing to look beyond the immediate quarter, BDMD presents an intriguing developing story: a relatively small publicly traded medical technology company attempting to build a global platform around minimally invasive ablation.

The real question now may not be whether Baird Medical has opportunities.

It may be how successfully the company can convert those opportunities into sustained U.S. adoption, recurring international revenue and a broader portfolio of commercially successful technologies.

For BDMD investors, the next several quarters could be particularly important.

For more information on BDMD visit: https://ir.bairdmed.com/ or https://www.compasslivemedia.com/bdmd/

Media Contact

Company Name: Baird Medical Investment Holdings Ltd. (Nas daq: BDMD)
Contact Person: Lee Roth, Burns McClellan for Baird Medical
Email: Lroth@burnsmc.com
Phone: (86) 20 8218-5926
Country: China